In this expert perspective from Hawaiian Eye 2024, Roger A. Goldberg, MD, MBA, discusses the significance of the approval of Vabysmo from Genentech for the treatment of retinal vein occlusion.
Retinal vein occlusion (RVO) is often overlooked in the retinal space, Goldberg said.
“We think about AMD and DME first and then RVO third,” he said. “But I think the approval of Vabysmo is the most important advance in 2023 for the treatment of RVO.”